Metabolic Syndrome Drug Market to Increase to Nearly $13 Billion By 2013
Posted on: Wednesday, 8 December 2004, 12:00 CST
WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, Inc., a global leader in research and advisory services focusing on pharmaceutical and health care issues, forecasts that major-market sales for metabolic syndrome drug treatments will increase at an annual rate of 2.8 percent to approximately $13 billion by 2013.
According to the new Pharmacor study entitled Metabolic Syndrome, this growth will be driven by the increasing acceptance of metabolic syndrome as a bona fide disorder that merits pharmacological treatment as an entity distinct from its individual disease components. Additionally, the launch of novel weight-loss agents and drugs that raise HDL cholesterol will contribute to the expansion of the metabolic syndrome market.
"There are varying clinical interpretations of metabolic syndrome because of the lack of a consensus definition, treatment guidelines, and agents specifically approved for this disorder," said Donny Wong, Ph.D., analyst at Decision Resources. "Despite these constraints, we estimate that, in 2003, the metabolic syndrome market totaled $9.7 billion in the United States, Europe, and Japan."
While analyzing sales for metabolic syndrome, Decision Resources focused on agents labeled for at least one of the underlying disease components -- type 2 diabetes, dyslipidemia, hypertension, and obesity -- that also have clinical effects on another risk factor.
About Metabolic Syndrome
Metabolic syndrome is a clustering of abnormalities that includes obesity, hyperglycemia, high blood pressure, and atherogenic dyslipidemia. Advances in scientific knowledge, the increasing prevalence of obesity, and the disorder's role in contributing to cardiovascular disease and diabetes are fueling interest in metabolic syndrome.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Major New Resource for Bone and Mineral Disorders Released
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- Expanding Obese Population and Improved Technology With Faster Outcomes Pump Up the U.S. Market for Obesity Surgery Devices
- Drug Treatment Market For Obesity Will Increase More Than Five-Fold, Reaching $2.7 Billion in 2016
- Will Metabolic Syndrome Emerge As a Commercial Market?
- Heart Metabolism Defect Linked to Disease
- Internal Relationship Management: Linking Human Resources to Market Performance
- Metabolic Syndrome Indicative of Future Heatlh Woes Obesity a Serious Problem Among Over-50 Crowd
- Can Adoption of Regular Exercise Later in Life Prevent Metabolic Risk for Cardiovascular Disease?
- Research and Markets: Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast
 |
 |
User Comments (0)
RSS Feeds